Costunolide and Parthenolide Ameliorate MPP+ Induced Apoptosis in the Cellular Parkinson’s Disease Model
Cells · 2023
DOI: 10.3390/cells12070992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Mehmet Enes Arslan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, 25100 Erzurum, Turkey. Hauptthemen laut MEDLINE: Parkinson Disease, Sesquiterpenes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Monoamine oxidase B (MAO-B) is an enzyme that metabolizes several chemicals, including dopamine. MAO-B inhibitors are used in the treatment of Parkinson’s Disease (PD), and the inhibition of this enzyme reduces dopamine turnover and oxidative stress. The absence of dopamine results in PD pathogenesis originating from decreased Acetylcholinesterase (AChE) activity and elevated oxidative stress. Here, we performed a molecular docking analysis for the potential use of costunolide and parthenolide terpenoids as potential MAO-B inhibitors in the treatment of PD. Neuroprotective properties of plant-originated costunolide and parthenolide terpenoids were investigated in a cellular PD model that was developed by using MPP+ toxicity. We investigated neuroprotection mechanisms through the analysis of oxidative stress parameters, acetylcholinesterase activity and apoptotic cell death ratios. Our results showed that 100 µg/mL and 50 µg/mL of costunolide, and 50 µg/mL of parthenolide applied to the cellular disease model ameliorated the cytotoxicity caused by MPP+ exposure. We found that acetylcholinesterase activity assays exhibited that terpenoids could ameliorate and restore the enzyme activity as in negative control levels. The oxidative stress parameter analyses revealed that terpenoid application could enhance antioxidant levels and decrease oxidative stress in the cultures. In conclusion, we reported that these two terpenoid molecules could be used in the development of efficient treatment strategies for PD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, 25100 Erzurum, Turkey.
- Department of Medical Biology, Faculty of Medicine, Atatürk University, 25240 Erzurum, Turkey.
- Department of Mathematics, Faculty of Science, Erzurum Technical University, 25100 Erzurum, Turkey.
- Science for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden.
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London SE1 9RT, UK.
ORCID-Profile: Mehmet Enes Arslan, Harun Selvitopi, Abdurrahim Kadi, Adil Mardinoğlu
Zitieren
APA
Arslan, M. E., Türkez, H., Sevim, Y., Selvitopi, H., Kadi, A., Öner, S., & Mardinoğlu, A. (2023). Costunolide and Parthenolide Ameliorate MPP+ Induced Apoptosis in the Cellular Parkinson’s Disease Model. Cells. https://doi.org/10.3390/cells12070992
Vancouver
Arslan ME, Türkez H, Sevim Y, Selvitopi H, Kadi A, Öner S, et al. Costunolide and Parthenolide Ameliorate MPP+ Induced Apoptosis in the Cellular Parkinson’s Disease Model. Cells. 2023. doi:10.3390/cells12070992
BibTeX
@article{Arslan2023,
author = {Arslan, Mehmet Enes and Türkez, Hasan and Sevim, Yasemin and Selvitopi, Harun and Kadi, Abdurrahim and Öner, Sena and Mardinoğlu, Adil},
title = {Costunolide and Parthenolide Ameliorate MPP+ Induced Apoptosis in the Cellular Parkinson’s Disease Model},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12070992}
}
EUVIMED